KR20070055373A - Composition for improving an atopy - Google Patents
Composition for improving an atopy Download PDFInfo
- Publication number
- KR20070055373A KR20070055373A KR1020060116301A KR20060116301A KR20070055373A KR 20070055373 A KR20070055373 A KR 20070055373A KR 1020060116301 A KR1020060116301 A KR 1020060116301A KR 20060116301 A KR20060116301 A KR 20060116301A KR 20070055373 A KR20070055373 A KR 20070055373A
- Authority
- KR
- South Korea
- Prior art keywords
- mushroom
- composition
- guava
- white
- fermented
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- 206010003645 Atopy Diseases 0.000 title description 11
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 201
- 241000508269 Psidium Species 0.000 claims abstract description 120
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 238000000855 fermentation Methods 0.000 claims abstract description 46
- 230000004151 fermentation Effects 0.000 claims abstract description 46
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 39
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 39
- 241000894006 Bacteria Species 0.000 claims abstract description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 28
- 239000004310 lactic acid Substances 0.000 claims abstract description 26
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 26
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000344 soap Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 9
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000002798 polar solvent Substances 0.000 claims description 7
- 244000233576 Feijoa sellowiana Species 0.000 claims description 6
- 235000012068 Feijoa sellowiana Nutrition 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 5
- 244000191482 Cantharellus cibarius Species 0.000 claims description 4
- 235000007821 Cattley guava Nutrition 0.000 claims description 4
- 244000233562 Psidium araca Species 0.000 claims description 4
- 235000012087 Psidium araca Nutrition 0.000 claims description 4
- 244000169711 Psidium cattleianum Species 0.000 claims description 4
- 244000236580 Psidium pyriferum Species 0.000 claims description 4
- 235000013929 Psidium pyriferum Nutrition 0.000 claims description 4
- 244000170064 Myrciaria floribunda Species 0.000 claims description 3
- 235000006994 Myrciaria floribunda Nutrition 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 2
- 241001070941 Castanea Species 0.000 claims description 2
- 235000014036 Castanea Nutrition 0.000 claims description 2
- 241000186610 Lactobacillus sp. Species 0.000 claims description 2
- 241001627205 Leuconostoc sp. Species 0.000 claims description 2
- 241001504654 Mustela nivalis Species 0.000 claims description 2
- 241000604136 Pediococcus sp. Species 0.000 claims description 2
- 244000168576 Psidium friedrichsthalianum Species 0.000 claims description 2
- 235000008722 Psidium friedrichsthalianum Nutrition 0.000 claims description 2
- 235000015126 Psidium littorale Nutrition 0.000 claims description 2
- 241000194022 Streptococcus sp. Species 0.000 claims description 2
- 235000019693 cherries Nutrition 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000779 smoke Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 241000131482 Bifidobacterium sp. Species 0.000 claims 3
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 241000023322 Myrciaria Species 0.000 claims 1
- 235000012063 Myrciaria Nutrition 0.000 claims 1
- 241000235088 Saccharomyces sp. Species 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 238000002474 experimental method Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000235070 Saccharomyces Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- -1 warnings Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 102000004003 Chemokine CCL11 Human genes 0.000 description 3
- 108010082548 Chemokine CCL11 Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 240000001462 Pleurotus ostreatus Species 0.000 description 3
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical class CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical class O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000414067 Inonotus obliquus Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Chemical class 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 244000297627 Senna alata Species 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical class CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 구아바 추출물을 버섯 균사체, 젖산균, 및/또는 효모로 발효시켜 얻어지는 구아바 발효 조성물을 이용한 아토피 피부염 개선제 조성물을 개시한다. The present invention discloses a composition for improving atopic dermatitis using a guava fermentation composition obtained by fermenting guava extract with mushroom mycelium, lactic acid bacteria, and / or yeast.
구아바, 발효, 조성물, 아토피 피부염 Guava, fermentation, composition, atopic dermatitis
Description
도 1은 본 발명의 아토피 피부염 개선제 조성물에 유효성분으로 포함되는 구아바 발효 조성물(A)과 구아바 비발효 조성물의 에오탁신-1의 생성 억제 활성을 대비하여 보여주기 위한 그래프이다.FIG. 1 is a graph showing a comparison of the activity of inhibiting the production of eotaxin-1 from the guava fermented composition (A) and the guava non-fermented composition as an active ingredient in the atopic dermatitis remedy composition of the present invention.
본 발명은 구아바 발효 조성물을 이용한 아토피 피부염 개선제 조성물에 관한 것이다.The present invention relates to a composition for improving atopic dermatitis using a guava fermented composition.
구아바(guajava)는 테르페노이드, 플라보노이드, 탄닌, 비타민, 여러 무기물질 등 여러 생리활성 물질을 지니고 있어 오래전부터 약용식물로 사용되어 온 식물이다. Guajava is a plant that has been used as a medicinal plant for a long time because it has various physiologically active substances such as terfenoid, flavonoid, tannin, vitamins and various inorganic substances.
특히 구아바는 항당뇨 활성, 항산화 활성, 항비만 활성, 항아토피 활성 등의 약리활성을 지닌다고 알려져 있다.Guava is known to have pharmacological activities such as antidiabetic activity, antioxidant activity, anti-obesity activity and anti-atopic activity.
구아바에 대한 연구는 크게 두 가지로 나누어 볼 수 있는데, 하나는 구아바 의 약리활성에 착안하여 구아바를 건강 기능성 식품으로 이용하고자 하는 연구이며, 다른 하나는 구아바의 약리활성을 강화시키고자 하는 연구이다.The research on guava can be divided into two kinds. One is to use guava as health functional food considering the pharmacological activity of guava, and the other is to strengthen the pharmacological activity of guava.
대한민국 공개특허 제2003-0026939호 등이 전자에 속하며, 대한민국 공개특허 제2005-0119336호 등이 후자에 속한다.Korean Patent Publication No. 2003-0026939, etc. belong to the former, and Korean Patent Publication No. 2005-0119336 belongs to the latter.
본 발명은 상기 후자의 경우와 같이 구아바가 지니는 약리활성 특히 항아토피 활성을 강화시키고자 하는 관점에서 완성된 것이다.The present invention has been completed in view of enhancing the pharmacological activity of guava, especially the anti-atopic activity, as in the latter case.
따라서 본 발명의 목적은 약리활성이 강화된 구아바 발효 조성물을 포함하는 아토피 피부염 개선제 조성물을 제공하는 데 있다. Accordingly, an object of the present invention is to provide an atopic dermatitis remedy composition comprising a guava fermented composition having enhanced pharmacological activity.
본 발명의 여타의 목적이나 구체적인 양태 등은 이하에서 개시될 것이다.Other objects, specific embodiments, etc. of the present invention will be described below.
본 발명은 구아바 발효 조성물을 포함하는 아토피 피부염 개선제 조성물을 제공한다.The present invention provides an atopic dermatitis remedy composition comprising a guava fermented composition.
본 발명자는, 하기 실시예 및 실험예에서 보여지듯이, 구아바 잎을 극성 용매(구체적으로는 물)로 추출하여 얻어진 추출물을 식용버섯인 상황버섯균사체 및/또는 차가버섯균사체와 젖산균 및/또는 효모액으로 발효시켜 얻어진 구아바 발효 조성물이, 발효되기 전의 구아바 잎 추출물보다는 더 높은 항아토피 활성을 가짐을 확인함으로써 본 발명을 완성한 것이다.As shown in the following Examples and Experimental Examples, the inventors of the present invention have found that extracts obtained by extracting guava leaves with a polar solvent (specifically, water) are mixed with mycelia of mushroom and / or mushroom mycelium and / or lactic acid bacteria and / , The present inventors have completed the present invention by confirming that the guava fermented composition obtained by fermentation with the extract has higher anti-atopic activity than the guava leaf extract before fermentation.
구체적으로, 본 발명자는 구아바 발효 조성물을 유효성분으로 하여 화장료을 제조하고 이를 아토피 피부염 질환을 앓고 있는 환자들에게 사용하도록 한 결과, 구아바 비발효 조성물(구아바 잎 추출물)이 포함된 화장료 조성물보다는 더 높게 아토피 피부염을 개선시키는 결과를 확인할 수 있었으며, 또한 구아바 발효 조성물은 구아바 비발효 조성물보다 아토피성 피부염의 홀마커(hallmarker)로 여겨지고 있는 에오탁신-1(Mol. Med., 1996 May;2(3):334-348; J Immunol. 2000 Apr. 1;164(7):3847-54.) 생성도 더 높게 억제함도 확인할 있었다.Specifically, the present inventors prepared a cosmetic composition using the guava fermented composition as an active ingredient, and applied it to patients suffering from atopic dermatitis. As a result, the present inventors have found that a cosmetic composition containing a guava non fermented composition (guava leaf extract) (Mol. Med., 1996 May; 2 (3): 1), which is considered to be a hallmark of atopic dermatitis than guava non-fermented composition, 334-348; J Immunol. 2000 Apr. 1; 164 (7): 3847-54).
본 발명은 이러한 실험 결과에 기초하여 제공되는 것이다.The present invention is provided based on the results of such experiments.
따라서 본 발명의 아토피 개선제 조성물은 하기 (a) 및 (b) 단계를 포함하는 제조방법에 의하여 얻어진 구아바 발효 조성물을 포함함을 특징으로 한다.Accordingly, the atopic modification composition of the present invention is characterized in that it comprises the guava fermentation composition obtained by the production method comprising the following steps (a) and (b).
(a) 구아바 잎을 극성 용매로 추출하는 단계, 및(a) extracting guava leaves with a polar solvent, and
(b) 그 추출물에 식용버섯 균사체를 접종하여 발효시키는 단계.(b) fermenting the extract to inoculate the edible mushroom mycelium.
청구범위를 포함하는 본 명세서에서, 상기 "구아바"란 일차적으로는 식물 분류학상 페시디움 속(Psidium sp .) 식물로서 구아바로 알려진 식물을 의미한다. 그러므로 상기 구아바는 본 발명의 하기 실시예에 사용된 페시디움 구아바(Psidium guajava L.) 뿐만 아니라, 구이사로(Guisaro; Psidium guinense SW.), 코스타 리칸 구아바(Costa Rican Guava; Psidium friendrichsthalianum Ndz.), 파라 구아바(Para Guava; Psidium acutangulum DC.)를 포함하는 의미로서 이해된다. In the present specification including claims, the term " guava "refers primarily to Psidium sp . ) Plants means plants known as guava. Thus, the guava, as well as the Passage Stadium guava (Psidium guajava L.) used in the examples of the present invention, roasted captured (Guisaro; Psidium guinense SW.), Costa Rican Guava ( Psidium friendrichsthalianum Ndz.), Para Guava ( Psidium acutangulum DC.).
한편, 캐틀레이 구아바(Cattley Guava), 스트로우베리 구아바(Strawberry Guava), 브라질리안 구아바(Brazilian Guava; Feijoa sellowiana Berg.). 구아바 베리(Guavaberry; Myrciaria floribunda Berg.), 파인애플 구아바(Pineapple Guava ; feijoa) 등 구아바의 유사 종으로 분류되고 있는 식물의 경우도, 본 발명의 실시예 및 실험예에 기초하는 한, 상기 식물의 잎을 극성 용매로 추출하고, 그 추출물을 버섯 균사체(및/또는 젖산균, 효모)로 발효시킬 경우에, 그 발효물이 항아토피 활성을 가질 것인가에 대한 예측, 확인·선별이 당업자의 통상의 능력 범위 내에 속하는 이상, 상기 "구아바"에 포함되는 것으로 간주 된다. Cattley Guava, Strawberry Guava, and Brazilian Guava (Feijoa sellowiana Berg). In the case of plants classified as similar species of guava, such as Guavaberry (Myrciaria floribunda Berg.) And Pineapple Guava (feijoa), as long as it is based on Examples and Experimental Examples of the present invention, The fermentation product is extracted with a polar solvent and the extract is fermented with mushroom mycelium (and / or lactic acid bacteria, yeast), prediction, confirmation and screening of whether or not the fermentation product has an anti- It is considered to be included in the above "Guava ".
이처럼, 청구범위를 포함하는 본 명세서에서 상기 "구아바"는 식물 분류학상 페시디움 속 식물로서 구아바로 알려진 식물 이외에 상기 열거한 구아바 유사 종을 포함하는 의미로서 이해되지만, 바람직하게는 본 발명의 하기 실시예 및 실험예에서 사용되고 실제 검증된 페시디움 구아바로 이해될 수 있다.As used herein, the term " guava "in the present specification including claims is understood to mean the guava species enumerated above in addition to the plants known as guava as a plant belonging to the genus Pseudomonas in plant taxonomic, Can be understood as feldium guava used in Examples and Experimental Examples and actually verified.
또한 청구범위를 포함하는 본 명세서에서, 상기 "극성 용매"란 극성을 띤 분자로 이루어진 용매를 의미하는데, 예컨대 물, 증류수, 에탄올 등의 탄소수가 5 이하의 저급 알콜, 에틸아세테이트, 아세톤, 클로로포름, 메틸렌클로라이드 또는 이들의 혼합 용매 등이 여기에 포함된다. In the present specification including the claims, the term "polar solvent" means a solvent composed of polar molecules, such as water, distilled water, lower alcohol having 5 or less carbon atoms such as ethanol, ethyl acetate, acetone, chloroform, Methylene chloride or a mixed solvent thereof, and the like.
또한 청구범위를 포함하는 본 명세서에서, 상기 "추출물"이란 액상 형태, 분말 형태의 추출물을 모두 포함하는 의미이다. 예컨대, 상기 구아바 잎을 알콜을 사용하여 추출할 경우, 그 추출물에 알콜이 남아 있는 경우에는 버섯 균사체가 생육하기에 적당하지 아니하므로, 이 때는 버섯 균사체에 의한 발효에 그 알콜이 제거된 분말 형태의 추출물을 사용하거나 그 분말 형태의 추출물을 물 등의 적당한 용매로 용해 또는 희석시켜 사용하는 것이 바람직하다. 참고로 본 발명의 하기 실시 예에서는 극성 용매인 물을 사용하였고, 그 얻어진 추출물을 고형분 함량이 20%가 될 때까지 농축시켜 버섯 균사체의 배양에 사용하였다.In the present specification including claims, the "extract" is meant to include both liquid and powdery extracts. For example, when the guava leaves are extracted using alcohol, if the alcohol is left in the extract, the mushroom mycelium is not suitable for growing. Therefore, in this case, when the alcohol is removed from the mushroom mycelium, It is preferable to use an extract or to dissolve or dilute the extract in powder form with a suitable solvent such as water. In the following examples of the present invention, water as a polar solvent was used, and the obtained extract was concentrated to a solid content of 20% and used for culturing mycelia of mushrooms.
또한 청구범위를 포함하는 본 명세서에서, 상기 "식용버섯"이란 사람이 식품 또는 약품으로 사용할 수 있는 버섯을 의미한다. 그러므로 상기 식용버섯에는 예컨대, 느타리 버섯, 노랑느타리버섯, 잣버섯, 벚꽃버섯(밤버섯), 붉은산무명버섯, 연기색만가닥버섯, 자주졸각버섯, 졸각버섯, 혹깔때기버섯, 하늘색깔때기버섯, 민자주방망이버섯, 왕송이버섯, 뽕나무버섯, 흰우단버섯, 굽은애기버섯, 끈적긴뿌리버섯, 긴뿌리버섯, 팽이버섯, 달걀버섯, 노란달걀버섯, 흰달걀버섯, 붉은점박이광대버섯, 우산버섯, 흰우산버섯, 흰비단털버섯, 풀버섯, 노란난버섯, 큰갓버섯, 주름버섯, 먹물버섯, 족제비눈물버섯, 개암버섯, 무리우산버섯, 붉은비단그물버섯, 기와버섯, 젖버섯, 꾀꼬리버섯, 나팔버섯, 흰국수버섯, 좀나무싸리버섯, 노루궁뎅이버섯, 턱수염버섯, 향버섯(능이), 까치버섯, 흰굴뚝버섯, 붉은덕다리버섯, 말징버섯, 말불버섯, 말뚝버섯, 망태버섯, 노랑망태버섯, 목이버섯, 털목이버섯, 흰목이버섯, 곰보버섯, 영지버섯, 신령버섯, 상황버섯, 차가버섯, 복령버섯, 장주버섯, 잎새버섯, 노루궁뎅이버섯, 능이버섯, 저령버섯, 표고버섯, 송이버섯, 잣버섯, 구름버섯, 꽃송이버섯, 치마버섯 등이 포함되는 것으로 이해되어야 한다. 다만, 바람직하게는 하기 실시예에서 사용된 상황버섯 또는 차가버섯으로 이해될 수 있다.In the present specification including claims, the above-mentioned "edible mushroom" means a mushroom that a person can use as food or medicine. Therefore, the above edible mushrooms include, for example, oyster mushroom, yellow oyster mushroom, pine nut mushroom, cherry mushroom (chestnut mushroom), red mushroom mushroom, smoke colored mushroom mushroom, frequent liquor mushroom, Oyster mushroom, white egg mushroom, red spotted mushroom, umbrella mushroom, red mushroom mushroom, white mushroom, red mushroom mushroom, red mushroom mushroom, white mushroom, white mushroom, White mushroom, white mushroom, mushroom, mushroom, yellow mushroom, large mushroom, wrinkle mushroom, mushroom, weasel mushroom, hazel mushroom, mushroom mushroom, red silk mushroom, tile mushroom, mushroom, Mushroom, white mushroom, red mushroom, red mushroom, mushroom mushroom, mushroom mushroom, yellow mushroom, yellow mushroom, white mushroom, white noodle mushroom, white noodle mushroom, Mushroom, throat mushroom, hairy Mushroom, mushrooms, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, mushroom Mushroom, mushroom, and mushroom. However, it can be understood as a mushroom or a mushroom preferably used in the following examples.
한편, 상기 본 발명의 구아바 발효 조성물을 얻기 위한 제조 방법에 있어서, 단계 (b)의 추출물은 당이 첨가된 추출물인 것이 바람직하다. 그것은 버섯 균사체에 그리고 후술하는 젖산균이나 효모에 탄소원/에너지원을 공급함으로써 발효가 보 다 효과적으로 이루어지도록 하기 위함이다. 상기 첨가되는 당은 버섯 균사체 등의 탄소원/에너지원으로 사용될 수 있는 것이면 무엇이든 상관없는데, 예컨대, 올리고당, 유당, 포도당, 과당, 설탕 등이 사용될 수 있다. 그것이 첨가되는 양은 단계 (b)의 추출물 중량을 기준으로 할 때 1 중량부 내지 15 중량부의 범위로 첨가될 수 있다.On the other hand, in the production method for obtaining the guava fermentation composition of the present invention, the extract of step (b) is preferably an extract in which sugar is added. It is to make the fermentation more effective by supplying the carbon source / energy source to the mushroom mycelium and to the lactic acid bacteria or yeast described later. The added sugars are not particularly limited so long as they can be used as a carbon source / energy source such as mycelia of mushroom, for example, oligosaccharides, lactose, glucose, fructose, sugar and the like. The amount to which it is added may be in the range of 1 to 15 parts by weight based on the weight of the extract of step (b).
또한 상기 본 발명의 구아바 발효 조성물을 얻기 위한 제조 방법에 있어서, 상기 (b) 단계 후에, 버섯 균사체의 발효물에 젖산균 및/또는 효모를 접종하여 추가로 발효시키는 단계가 포함되는 것이 바람직하다. 그것은 하기 실험예가 보여주듯이, 구아바 잎의 추출물을 버섯 균사체만으로 발효시킨 경우보다 젖산균 및/또는 효모를 접종하여 추가로 발효시킨 경우가 그 항아토피 활성이 더 우수한 것으로 나타났기 때문이다. 특히 버섯 균사체의 발효물에 젖산균과 효모 모두를 접종하여 발효시키는 경우가 항아토피 활성에 있어서 가장 우수하였다. 그러므로 상기 본 발명의 구아바 발효 조성물을 얻기 위한 제조 방법에 있어서, 상기 (b) 단계 후에, 버섯 균사체의 발효물에 젖산균 및 효모 모두를 접종하여 추가로 발효시키는 단계가 포함되는 것이 바람직하다. Further, in the method for producing the guava fermentation composition of the present invention, it is preferable that the step (b) further includes a step of inoculating lactic acid bacteria and / or yeast into the fermented product of the mushroom mycelium to further ferment. This is because, as shown in the following experimental example, when the extract of guava leaves is fermented by mycelia only, lactic acid bacteria and / or yeast are inoculated and fermented more effectively than the mushroom mycelium. Especially, fermentation of lactic acid bacteria and yeast in fermented product of mushroom mycelium was the best in anti - atopic activity. Therefore, in the production method for obtaining the guava fermentation composition of the present invention, it is preferable that after the step (b), the lactic acid bacteria and the yeast are all inoculated to the fermented product of the mushroom mycelium to further ferment.
또한 상기 본 발명의 구아바 발효 조성물을 얻기 위한 제조 방법에 있어서, 구아바 잎 추출물을 버섯 균사체로 발효시키거나, 버섯 균사체 발효물을 젖산균이나 효모로 발효시킬 때, 각 발효 단계 이전에 구아바 잎 추출물 또는 그 발효물의 멸균 단계를 포함하는 것이 바람직하다. 그것은 타균에 의한 원치 않는 발효가 진행되는 것을 저지시키기 위한 것이다. 여기서 멸균 단계의 수행은 자외선 조사, 고 압·고온 처리 등 당업계에 알려진 임의의 방법에 의하여 이루어질 수 있다.In addition, in the method for producing the guava fermentation composition of the present invention, when the Guava leaf extract is fermented with mushroom mycelia or when the fermented mushroom mycelium is fermented with lactic acid bacteria or yeast, the guava leaf extract or its It is preferable to include a step of sterilizing the fermented product. It is intended to prevent undesirable fermentation by bacterium from proceeding. Here, the sterilization step may be carried out by any method known in the art, such as ultraviolet irradiation, high pressure and high temperature treatment.
또한 상기 본 발명의 구아바 발효 조성물을 얻기 위한 제조 방법에 있어서, 상기 발효 단계는 그것이 버섯 균사체에 의한 것이든, 젖산균에 의한 것이든 또는 효모에 의한 것이든 충분히 수행되는 것이 바람직하다. 여기서 "충분히"란 버섯 균사체나 젖산균 또는 효모가 이미 최대로 증식함으로써 더 이상 증식하지 않는 단계로서 이해될 수 있다. 어느 정도의 기간 동안 발효되어야 충분히 발효된 것이냐는 발효 생물체 및 발효 온도와의 관계에서 결정되는데, 당업자라면 그의 통상의 능력 범위에서 특정 온도에서 생물체의 종류에 따라 충분히 발효되는 시간을 용이하게 확정할 수 있을 것이다. 하기 본 발명의 실시예에서는 버섯 균사체의 경우는 25℃에서 약 15일 정도 발효를 수행하였고 젖산균 및 효모의 경우는 38℃에서 7일 정도 발효를 수행하였다.In addition, in the production method for obtaining the guava fermented composition of the present invention, it is preferable that the fermentation step is sufficiently carried out whether it is by mycelium of mushroom, lactic acid bacteria or yeast. Here, "sufficient" can be understood as a step in which mushroom mycelium, lactic acid bacteria, or yeast are already proliferated to no longer proliferate. Whether or not fermentation is sufficient for fermentation for a certain period of time is determined in relation to the fermentation organism and the fermentation temperature. Those skilled in the art can easily determine the time for sufficient fermentation according to the kind of organism at a certain temperature There will be. In the examples of the present invention, fermentation was carried out at 25 ° C. for about 15 days in the case of mushroom mycelium, and in fermentation at 38 ° C. for 7 days in the case of lactic acid bacteria and yeast.
가장 바람직한 양태에 있어서, 상기 본 발명의 구아바 발효 조성물은 하기 <실시예 4 및 8>에 개시된 공정과 조건으로 발효시켜 얻어진 것을 의미한다. 그것은 하기 <실시예 4 및 8>에서 얻어진 구아바 발효 조성물이 항산화 활성, 항미생물 활성, 항염증 활성 및/또는 항아토피 활성에 있어 가장 우수하였기 때문이다.In the most preferred embodiment, the guava fermented composition of the present invention means that the guava fermented composition of the present invention is obtained by fermentation under the conditions and conditions described in the following Examples 4 and 8. This is because the guava fermentation composition obtained in the following <Examples 4 and 8> was superior in antioxidative activity, antimicrobial activity, anti-inflammatory activity and / or anti-atopic activity.
구체적으로 상기 본 발명의 구아바 발효 조성물이 하기 단계 (a) 내지 (f)를 포함하는 제조방법에 의하여 얻어진 것을 말한다. Specifically, it means that the guava fermentation composition of the present invention is obtained by a manufacturing method comprising the following steps (a) to (f).
(a) 구아바 잎을 열수추출하여 그 여과액을 얻는 단계.(a) hot water extraction of guava leaves to obtain a filtrate thereof.
(b) 상기 여과액을 당과 혼합하는 단계.(b) mixing the filtrate with the sugar.
(c) 상기 여과액과 당의 혼합물을 멸균하는 단계.(c) sterilizing the filtrate and the sugar mixture.
(d) 상기 멸균된 혼합물에 상황버섯 균사체 또는 차가버섯 균사체를 접종하여 상온에서 25℃에서 15일 이상 발효시키는 단계.(d) inoculating the mycelium of mushroom mycelia or mycelia of mushroom to the sterilized mixture, and fermenting the mushroom mycelium at room temperature for at least 15 days at 25 ° C.
(e) 상기 버섯 균사체의 발효물을 멸균하는 단계, 및(e) sterilizing the fermented product of the mushroom mycelium, and
(f) 상기 멸균된 발효물에 락토바실러스 플란타럼(Lactobacillus plantarum ) 및 사카로마이세스 세레비시아에를 접종하여 38℃에서 7일 이상 발효시키는 단계.(f) the step of inoculated to the above sterile fermentation Lactobacillus Planta column (Lactobacillus plantarum) and a saccharide as MY process three Levy cyano fermentation than in 38 ℃ 7 days.
한편, 청구범위를 포함하는 본 명세서에서, 상기 "젖산균"이란 클루코스 등 당류를 분해하여 젖산을 생성하는 세균으로 이해될 수 있다. 젖산균은 락토바실러스속 젖산균(Lactobacillus sp .), 스트렙토코쿠스속 젖산균(Streptococcus sp .), 페디오코쿠스속 젖산균(Pediococcus sp .), 류코노스톡속 젖산균(Leuconostoc sp .) 및 비피도박테리움속 젖산균(Bifidobacterium sp .)으로 대별되는데, 상기 젖산균은 이러한 모든 젖산균을 모두 포함하는 의미로서 이해된다. 다만, 하기 실시예에서 락토바실러스 플란타럼이 사용되었다는 점에서, 바람직하게는 상기 젖산균은 락토바실러스속 젖산균으로 이해될 수 있으며, 특히 락토바실러스 플란타럼으로 이해될 수 있다. On the other hand, in the present specification including claims, the above-mentioned "lactic acid bacteria" can be understood as a bacterium which decomposes saccharides such as clocose to produce lactic acid. Lactic acid bacteria can be selected from the group consisting of Lactobacillus sp . , Streptococcus sp . , Pediococcus sp . sp . ), Lactobacillus lactic acid bacteria ( Leuconostoc sp . ) And Bifidobacterium ( Bifidobacterium < RTI ID = 0.0 > sp . ). The above-mentioned lactic acid bacteria are understood to include all of these lactic acid bacteria. However, since lactobacillus plantarum is used in the following examples, preferably, the lactobacillus can be understood as lactobacillus in the genus Lactobacillus, and in particular, can be understood as Lactobacillus plantarum.
또한 청구범위를 포함하는 본 명세서에서, 상기 "효모"란 사카로마이세스 속 효모를 의미하며, 예컨대 사카로마이세스 루시(Saccharomyces rouxii), 사카로마이세스 세레비시아에(Saccharomyces cereviciae), 사카로마이세스 오비폴미스(Saccharomyces oviformis), 사카로마이세스 스테이네리(Saccharomyces steineri) 등을 포함하는 의미이다.Also, in the present specification including claims, the "yeast" refers to the genus Saccharomyces Refers to yeast, such as Saccharomyces lysi in rouxii), my process three Levy cyano as Saccharomyces (Saccharomyces cereviciae), my process Ob pole miss in Saccharomyces (Saccharomyces oviformis), saccharose in my process stay Neri (Saccharomyces steineri ) and the like.
또한 청구범위를 포함하는 본 명세서에서, 상기 "아토피 피부염"은 그 발생 의 직·간접적인 원인을 불문하고 당업계에서 아토피 피부염으로 분류되는 모든 질환을 포함하는 것으로 정의된다. 통상 아토피 피부염은 그 발병 시기 또는 그 발명 대상에 따라 유아형 아토피 피부염과 소아형 아토피 피부염과 성인형 아토피 피부염 그리고 임산부 아토피 피부염으로 분류되는데, 본 명세서에서 아토피 피부염은 이러한 모든 유형의 아토피 피부염을 포함하는 것으로서 정의된다. 본 발명의 아토피 피부염 개선용 조성물이 상기 모든 유형의 아토피 피부염을 개선시키는 효과가 있을 것임은 본 발명의 하기 실시예 및 실험예에서 확인되는 바이다.In the present specification, including the claims, the term "atopic dermatitis" is defined as including any disease classified as atopic dermatitis in the art, regardless of the cause, either directly or indirectly. In general, atopic dermatitis is classified into infantile atopic dermatitis, infantile atopic dermatitis, adult atopic dermatitis, and mothergic atopic dermatitis according to the onset period or the object of the invention. In this description, atopic dermatitis includes all types of atopic dermatitis . It is confirmed in the following Examples and Experimental Examples of the present invention that the composition for improving atopic dermatitis of the present invention will have the effect of improving all types of atopic dermatitis.
또한 청구범위를 포함하는 본 명세서에서, 상기 "개선"이란 치료, 예방 또는 증상의 경감을 의미한다.In the present specification, including the claims, the "improvement" means treatment, prevention, or alleviation of symptoms.
한편, 본 발명의 아토피 피부염 개선용 조성물에 있어서, 그 유효성분인 구아바 발효 조성물은 본 발명의 아토피 피부염 개선용 조성물에 아토피 피부염의 증상의 정도에 따라 그것이 인체에의 독성을 미치지 않는 범위 내에서 임의의 양으로 포함될 수 있는데, 구체적으로 조성물 전체 중량을 기준으로 할 때 0.001 중량 % 내지 99.99 중량 %로 포함될 수 있으며, 바람직하게는 0.001 중량 % 내지 20 중량 %로 포함될 수 있다. Meanwhile, in the composition for improving atopic dermatitis of the present invention, the guava fermented composition which is an effective ingredient thereof may be added to the composition for improving atopic dermatitis of the present invention in a range that does not adversely affect the human body, depending on the degree of symptoms of atopic dermatitis And may be contained in an amount of 0.001% by weight to 99.99% by weight, preferably 0.001% by weight to 20% by weight, based on the total weight of the composition.
구체적인 양태에 있어서, 본 발명의 아토피 피부염 개선제 조성물은 약제학적 조성물로 파악될 수 있다.In a specific embodiment, the atopic dermatitis remedy composition of the present invention can be identified as a pharmaceutical composition.
본 발명의 약제학적 조성물은 유효 성분으로서 구아바 발효 조성물 이외에 약제학적으로 허용되는 담체를 포함할 수 있는데, 이러한 약제학적으로 허용되는 담체는 약품 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크 로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘, 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 또한 첨가제로서 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier in addition to the guava fermented composition as an active ingredient. Such pharmaceutically acceptable carriers are those conventionally used in pharmaceutical preparations, and include lactose, dextrose, But are not limited to, lactose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, Carboxymethylcellulose, carboxymethylcellulose, hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like. The pharmaceutical composition of the present invention may further comprise, as an additive, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative and the like.
상기 담체는 본 발명의 약제학적 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.999 중량 %, 바람직하게는 약 50 중량% 내지 약 99.999 중량 %로 포함될 수 있으며, 상기 첨가제는 약 0.1 중량 % 내지 약 20 중량 %로 포함될 수 있다. The carrier may be included in the pharmaceutical composition of the present invention in an amount of about 1% by weight to about 99.999% by weight, preferably about 50% by weight to about 99.999% by weight, based on the total weight of the pharmaceutical composition, To about 20% by weight.
한편, 본 발명의 약제학적 조성물은 아토피 피부염의 증상 정도에 따라 투여 방법이 결정되는데, 통상적으로는 국소 투여 방식이 적합할 것이다.Meanwhile, the pharmaceutical composition of the present invention determines the administration method according to the degree of symptoms of atopic dermatitis. Usually, local administration method is suitable.
본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기내에 내입시켜 제조될 수 있다. 이때 제형은 용액, 현탁액 또는 유화액 형태이거나 엘렉시르제, 엑스제, 분말제, 과립제, 정제, 경고, 도고제, 로션, 연고 등의 형태일 수 있다.The pharmaceutical composition of the present invention can be prepared in unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient or can be manufactured by inserting it into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions, or may be in the form of devices such as elixirs, extracts, powders, granules, tablets, warnings, lozenges, lotions, ointments and the like.
본 발명의 약제학적 조성물은 그 1일 투여량이 통상 0.001 ~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 본 발명의 약제학적 조성물의 투여량은 투여 경로, 환자의 연령, 성별, 체중, 환자의 중증도 등의 여러 관련 인자에 비추어 결정되어지는 것이므로 상기 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 아니 된다. The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various factors such as route of administration, age, sex, weight, and patient's severity of the patient, the dose is limited in any aspect to the range of the present invention. Should not be construed as doing.
다른 구체적인 양태에 있어서, 본 발명의 아토피 피부염 개선제 조성물은 기능성 식품 조성물로서 파악될 수 있다. In another specific embodiment, the atopic dermatitis remedy composition of the present invention can be identified as a functional food composition.
본 발명의 기능성 식품 조성물은 껌류, 비타민 복합제, 건강 보조식품, 특수 영양 보충용 식품, 기능성 음료 등으로 제조될 수 있다.The functional food composition of the present invention can be manufactured from gums, a vitamin complex, a health supplement, a food for special supplement, or a functional drink.
본 발명의 기능성 식품 조성물에는 유효성분인 구아바 발효 조성물이 포함되는 것 이외에, 포도당, 과당과 같은 단당류, 말토스, 슈크로스와 같은 이당류, 또는 덱스트린, 사이클로덱스트린과 같은 다당류가 첨가될 수 있고, 자일리톨, 소르비톨, 에리트리톨 등의 당 알콜이 또한 첨가될 수 있으며, 타우린, 스테비아 추출물과 같은 감미제 등이 또한 첨가될 수 있다. The functional food composition of the present invention may contain, in addition to the active ingredient guava fermented composition, disaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, or polysaccharides such as dextrin and cyclodextrin, , Sugar alcohols such as sorbitol and erythritol may also be added, and sweetening agents such as taurine and stevia extract may also be added.
또 다른 구체적인 양태에 있어서, 본 발명의 아토피 피부염 개선제 조성물은 화장료 조성물로서 파악될 수 있다. 본 발명의 아토피 피부염 개선제 조성물이 화장료 조성물로서 파악될 경우, 그 화장료 조성물은 다양한 형태로 제조될 수 있는데, 예컨대, 에멀젼, 로션, 크림(수중유적형, 유중수적형, 다중상), 용액, 현탁액(무수 및 수계), 무수 생성물(오일 및 글리콜계), 젤, 마스크, 팩, 분말 등의 형태로 제조될 수 있다.In another specific embodiment, the atopic dermatitis remedy composition of the present invention can be identified as a cosmetic composition. When the atopic dermatitis remedy composition of the present invention is identified as a cosmetic composition, the cosmetic composition may be prepared in various forms such as emulsion, lotion, cream (underwater type, water type, multiphase), solution, suspension (Anhydrous and aqueous), anhydrous products (oil and glycol), gels, masks, packs, powders and the like.
본 발명의 화장료 조성물은 그 유효성분인 구아바 발효 조성물 이외에 화장료 제제에 있어서 수용가능한 담체를 포함할 수 있다. The cosmetic composition of the present invention may contain an acceptable carrier in cosmetic preparations in addition to the guava fermentation composition as an effective ingredient thereof.
여기서 "화장료 제제에 있어서 수용가능한 담체"란 화장료 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 이상의 독성, 불안정성 또는 자극성이 없는 것을 말한다.As used herein, the term "acceptable carrier for cosmetic preparation" means a compound or composition which is already known and used in the cosmetic preparation, or which is a compound or composition to be developed in the future, and which has no toxicity, instability or irritability It says.
상기 담체는 본 발명의 아토피 피부염 개선제 화장료 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.999 중량 %, 바람직하게는 조성물의 중량의 약 50 중량% 내지 약 99.999 중량 %로 포함될 수 있다. 그러나 이러한 비율은 본 발명의 아토피 피부염 개선제 화장료 조성물이 제조되는 전술한 바의 형태에 따라 또 그것의 구체적인 적용 부위(얼굴, 목 등)나 그것의 바람직한 적용량 등에 따라 달라지는 것이기 때문에, 상기 비율은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 안 된다. The carrier may be included in the atopic dermatitis-improving agent cosmetic composition of the present invention in an amount of about 1 wt% to about 99.999 wt%, preferably about 50 wt% to about 99.999 wt%, based on the total weight of the composition. However, since the ratio varies depending on the above-described form in which the atopic dermatitis remedy cosmetic composition of the present invention is produced and its specific application site (face, neck, etc.) or its preferable application amount, Should not be construed as limiting the scope of the invention.
한편, 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 등이 예시될 수 있다. Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosifiers, emulsifiers, stabilizers, sunscreens, coloring agents and perfumes.
상기 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료로 사용될 수 있는 화합물/조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다.The compounds / compositions that can be used as the above-mentioned alcohol, oil, surfactant, fatty acid, silicone oil, humectant, humectant, viscosifier, emulsion, stabilizer, ultraviolet screening agent, coloring agent and fragrance are already known in the art The appropriate substance / composition can be selected and used.
또 다른 구체적인 양태에 있어, 본 발명의 아토피 피부염 개선제 조성물은 비누 조성물로서도 파악될 수 있다.In another specific embodiment, the atopic dermatitis remedy composition of the present invention can also be identified as a soap composition.
본 발명의 아토피 피부염 개선제 조성물이 비누 조성물로서 파악될 경우에, 본 발명의 비누 조성물은 비누 기재에 구아바 발효 조성물을 포함시켜 제조될 수 있으며, 첨가제로서 피부 보습제, 유화제, 경수연화제 등을 포함시켜 제조될 수 있다.When the atopic dermatitis remedy composition of the present invention is identified as a soap composition, the soap composition of the present invention can be prepared by incorporating a guava fermented composition into a soap base material, and includes a skin moisturizer, an emulsifier, a water softener, .
상기 비누 기재로서는 야자유, 팜유, 대두유, 파마자유, 올리브유, 팜핵류 등의 식물유지 또는 우지, 돈지, 양지, 어유 등의 동물유지 등이 사용될 수 있고, 상기 피부 보습제로서는 글리세린, 에리트리톨, 폴리에틸렌글리콜, 프로필렌글리콜, 부틸렌글리콜, 펜틸렌글리콜, 헥실글리콜, 이소프로필미리스테이트, 실리콘 유도체, 알로에베라, 솔비톨 등이 사용될 수 있으며, 상기 유화제로서는 천연오일, 왁스 지방알콜, 탄화수소류, 천연식물 추출물 등이 사용될 수 있고, 상기 경수연화제로서는 테트라소듐 이디티에이 등이 사용될 수 있다.Examples of the soap base material include vegetable oils such as palm oil, palm oil, soybean oil, perm free oil, olive oil and palm kernel oil or animal fats such as tallow, lard, sunshine and fish oil. Examples of the skin moisturizers include glycerin, erythritol, polyethylene glycol , Propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol and the like. Examples of the emulsifier include natural oils, wax fatty alcohols, hydrocarbons, May be used. As the water softening agent, tetrasodium ethylenediate and the like may be used.
본 발명의 비누 조성물은 또한 첨가제로서 항균제, 분산제, 거품억제제, 용매, 물때 방지제, 부식 방지제, 향료, 색소, 금속이온 봉쇄제, 산화방지제, 방부제 등을 추가적으로 포함할 수 있다.The soap composition of the present invention may further contain, as an additive, an antibacterial agent, a dispersant, a foam inhibitor, a solvent, a scouring inhibitor, a corrosion inhibitor, a fragrance, a dye, a sequestering agent, an antioxidant and an antiseptic.
본 발명의 비누 조성물에 있어서, 비누 기재나 첨가제는 당업계에 일반적으로 사용되고 있는 함량으로 포함될 수 있는데, 비누 기재는 일반적으로 비누 조성물의 전체 중량을 기준으로 하였을 때 1 중량 % 내지 99.999 중량 %로 첨가될 수 있으며, 첨가제는 1 중량 % 내지 20 중량 %로 첨가될 수 있다.In the soap composition of the present invention, the soap base or additive may be included in a content commonly used in the art, wherein the soap base generally comprises from 1% to 99.999% by weight, based on the total weight of the soap composition And the additive may be added in an amount of 1 wt% to 20 wt%.
이하 본 발명을 실시예 및 실험예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예 및 실험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.
<< 실시예Example > > 구아바Guava 발효 조성물의 제조 Preparation of fermentation composition
<실시예 1> 구아바 발효 조성물의 제조예 1 Example 1 Production of Guava Fermented Composition Example 1
시중에서 구입한 구아바(Psidium guajava L.)의 잎을 건조시키고, 분쇄하여 미세 분말을 만든 후, 분말 5 kg을 취하여 여기에 물을 100ℓ를 넣은 후, 95℃에서 5시간 동안 추출하였다. 이렇게 얻어진 추출물을 여과시켜 10 ㎛ 이상의 입자를 제거하고, 여과액을 50℃에서 고형분 함량 20%가 될 때까지 농축한 후, 그 얻어진 농축물 2ℓ에 당밀 40g을 첨가하고, 120℃, 1.4기압 하에서 20분간 처리하여 농축물을 멸균하였다. 멸균된 농축물에 PDB(Potato Dextrose Broth)배지로 15일간 25℃, 110rpm 조건에서 배양된 상황버섯균사체( Phellinus linteus KCTC 4212) 배양액 100㎖를 넣은 후, 25℃에서 15일 동안 발효시켜 구아바 발효 조성물을 제조하였다. 이렇게 얻어진 구아바 발효 조성물은 100℃에서 10분간 살균처리한 후 하기 실험에 이용하였다.The leaf of Psidium guajava L. purchased from the market was dried and pulverized to make a fine powder. 5 kg of powder was taken and 100 L of water was added thereto, followed by extraction at 95 ° C for 5 hours. The extract thus obtained was filtered to remove particles of 10 mu m or more. The filtrate was concentrated at 50 DEG C to a solid content of 20%, 40 g of molasses was added to 2 liters of the obtained concentrate, The concentrate was sterilized by treatment for 20 minutes. The 15-day PDB (Potato Dextrose Broth) medium in a sterile concentrate 25 ℃, cultured at 110rpm conditions Phellinus mycelium (Phellinus linteus KCTC 4212) culture broth, and fermented at 25 캜 for 15 days to prepare a guava fermented composition. The thus-obtained guava fermented composition was sterilized at 100 DEG C for 10 minutes and used in the following experiment.
<실시예 2> 구아바 발효 조성물의 제조예 2 Example 2 Production of Guava Fermented Composition Example 2
살균 처리한 상기 <실시예 1>의 구아바 발효 조성물 약 2ℓ에 젖산균(Lactobacillus plantarum ATCC8014) 배양액 100㎖를 첨가하여 38℃에서 7일 동안 발효시켜 구아바 발효 조성물을 제조하였다. 이렇게 얻어진 구아바 발효 조성물은 100℃에서 10분간 살균처리한 후 하기 실험에 이용하였다.To about 2 L of the guava fermentation composition of the above <Example 1> sterilized, lactic acid bacteria ( Lactobacillus plantarum ATCC8014) culture medium was added and fermented at 38 DEG C for 7 days to prepare a guava fermented composition. The thus-obtained guava fermented composition was sterilized at 100 DEG C for 10 minutes and used in the following experiment.
<실시예 3> 구아바 발효 조성물의 제조예 3 Example 3 Production of Guava Fermented Composition Example 3
살균 처리한 상기 <실시예 1>의 구아바 발효 조성물 약 2ℓ에 효모(Saccharomyces cerevisiae; IFO0203) 배양액 100㎖를 첨가하여 38℃에서 7일 동안 발효시켜 구아바 발효 조성물을 제조하였다. 이렇게 얻어진 구아바 발효 조성물은 100℃에서 10분간 살균처리한 후 하기 실험에 이용하였다.100 ml of yeast ( Saccharomyces cerevisiae ; IFO0203) culture was added to about 2 L of the guava fermentation composition of Example 1, which was sterilized, and fermented at 38 DEG C for 7 days to prepare a guava fermented composition. The thus-obtained guava fermented composition was sterilized at 100 DEG C for 10 minutes and used in the following experiment.
<실시예 4> 구아바 발효 조성물의 제조예 4 Example 4 Production of Guava Fermented Composition Example 4
살균 처리한 상기 <실시예 1>의 구아바 발효 조성물 약 2ℓ에 젖산균(Lactobacillus plantarum ATCC8014) 배양액과 효모(Saccharomyces cerevisiae; IFO0203) 배양액의 1:1 혼합물 100㎖를 첨가하여 38℃에서 7일 동안 발효시켜 구아바 발효 조성물을 제조하였다. 이렇게 얻어진 구아바 발효 조성물은 100℃에서 10분간 살균처리한 후 하기 실험에 이용하였다.To about 2 L of the guava fermentation composition of the above <Example 1> sterilized, lactic acid bacteria ( Lactobacillus plantarum ATCC 8014) and yeast ( Saccharomyces cerevisiae ; IFO0203) culture broth was added and fermented at 38 DEG C for 7 days to prepare a guava fermented composition. The thus-obtained guava fermented composition was sterilized at 100 DEG C for 10 minutes and used in the following experiment.
<실시예 5> 구아바 발효 조성물의 제조예 5 Example 5 Production of Guava Fermented Composition Example 5
상기 <실시예 1>과 동일한 재료, 공정 및 조건으로 구아바 발효 조성물을 제조하되, 상황버섯균사체 배양액 대신에 차가버섯균사체(Inonotus obliquus; KCTC 18572) 배양액을 사용하여, 구아바 발효 조성물을 제조하였다.A guava fermented composition was prepared by the same materials, processes, and conditions as those in Example 1 except that the mushroom mycelium ( Inonotus obliquus ; KCTC 18572) culture was used to prepare a guava fermented composition.
<실시예 6> 구아바 발효 조성물의 제조예 6 Example 6 Production of Guava Fermented Composition Example 6
살균 처리한 상기 <실시예 5>의 구아바 발효 조성물 약 2ℓ에 젖산균(Lactobacillus plantarum ATCC8014) 배양액 100㎖를 첨가하여 38℃에서 7일 동안 발효시켜 구아바 발효 조성물을 제조하였다. 이렇게 얻어진 구아바 발효 조성물은 100℃에서 10분간 살균처리한 후 하기 실험에 이용하였다.To about 2 L of the guava fermentation composition of Example 5, which had been sterilized, was added lactic acid bacteria ( Lactobacillus plantarum ATCC8014) culture medium was added and fermented at 38 DEG C for 7 days to prepare a guava fermented composition. The thus-obtained guava fermented composition was sterilized at 100 DEG C for 10 minutes and used in the following experiment.
<실시예 7> 구아바 발효 조성물의 제조예 7 Example 7 Production of Guava Fermented Composition Example 7
살균 처리한 상기 <실시예 5>의 구아바 발효 조성물 약 2ℓ에 효모(Saccharomyces cerevisiae; IFO0203) 배양액 100㎖를 첨가하여 38℃에서 7일 동안 발효시켜 구아바 발효 조성물을 제조하였다. 이렇게 얻어진 구아바 발효 조성물은 100℃에서 10분간 살균처리한 후 하기 실험에 이용하였다.100 ml of yeast culture ( Saccharomyces cerevisiae ; IFO0203) was added to about 2 L of the guava fermented composition of Example 5, which was sterilized, and fermented at 38 DEG C for 7 days to prepare a guava fermented composition. The thus-obtained guava fermented composition was sterilized at 100 DEG C for 10 minutes and used in the following experiment.
<실시예 8> 구아바 발효 조성물의 제조예 8 Example 8 Production of Guava Fermented Composition Example 8
살균 처리한 상기 <실시예 1>의 구아바 발효 조성물 약 2ℓ에 젖산균(Lactobacillus plantarum ATCC8014) 배양액과 효모(Saccharomyces cerevisiae; IFO0203) 배양액의 1:1 혼합물 100㎖를 첨가하여 38℃에서 7일 동안 발효시켜 구아바 발효 조성물을 제조하였다. 이렇게 얻어진 구아바 발효 조성물은 100℃에서 10분간 살균처리한 후 하기 실험에 이용하였다.To about 2 L of the guava fermentation composition of the above <Example 1> sterilized, lactic acid bacteria ( Lactobacillus plantarum ATCC 8014) and yeast ( Saccharomyces cerevisiae ; IFO0203) culture broth was added and fermented at 38 DEG C for 7 days to prepare a guava fermented composition. The thus-obtained guava fermented composition was sterilized at 100 DEG C for 10 minutes and used in the following experiment.
<< 비교예Comparative Example > > 구아바Guava 비발효Non fermentation 조성물의 제조 Preparation of composition
구아바 비발효 조성물은 발효 전 상태에 있는 <실시예 1>의 구아바 열수 추 출물의 여과액의 농축물을 말한다. 하기 실험에서는 이 농축물을 120℃, 1.4기압 하에서 20분간 멸균 처리하여 사용하였다.The non-fermented guava composition refers to a concentrate of the filtrate of the guava hot water extract of Example 1 in the pre-fermentation state. In the following experiment, the concentrate was sterilized for 20 minutes at 120 ° C and 1.4 atm.
<< 실험예Experimental Example > > 구아바Guava 발효 조성물의 Of the fermentation composition 항아토피Anti-atopic 활성 실험 Active experiment
<실험예 1> 에오탁신-1의 억제 활성 실험Experimental Example 1 Inhibitory activity of eotaxin-1
NIH3T3 섬유 아세포(1 x 106 cells/㎖)를 24 웰 플레이트에서 18 시간 배양하고 여기에 TNF-α(10ng/ml)를 처리하여 에오탁신-1의 발현을 유도하고 동시에 0.001%, 0.005%, 0.01%, 0.05% 농도의 시료(<실시예 4>의 구아바 발효 조성물 및 <비교예>의 구아바 비발효 조성물)를 처리하여, 16 시간 동안 배양한 다음 세포배지를 50 ㎕씩 수집하였다. 수집된 세포배지를 이용하여 R&D systems의 protocol(Kor. J. Pharmacogn. 2003, 34(3) 228-232)에 따라 에토탁신-1의 양을 측정하였다. 결과를 도 1에 나타내었는데, 비교예의 구아바 비발효 조성물(A)은 에오탁신-1의 발현을 억제하지 못하였으나, 실시예 4(B)의 구아바 발효 조성물은 에오탁신-1의 발현을 농도 의존적으로 억제하였음을 알 수 있다.The cells were cultured in a 24-well plate for 18 hours with NIH3T3 fibroblasts (1 x 10 6 cells / ml) and treated with TNF-α (10 ng / ml) to induce expression of eotaxin- %, 0.05% concentration of the sample (the guava fermented composition of Example 4 and the guava non-fermented composition of the comparative example) were cultured for 16 hours, and then 50 μl of the cell culture medium was collected. The amount of ethotoxin-1 was measured according to the protocol of R & D systems (Kor. J. Pharmacogn. 2003, 34 (3) 228-232) using the collected cell culture medium. The results are shown in Fig. 1. The guava non-fermented composition (A) of the comparative example did not inhibit the expression of eotaxin-1, but the guava fermented composition of Example 4 (B) As shown in Fig.
<실험예 2> 아토피 치료에 대한 관능평가 <Experimental Example 2> Sensory evaluation for atopic treatment
먼저, 실시예의 각 구아바 발효 조성물 또는 비교예의 구아바 비발효 조성물 1.5g, 스테아린산 2.0g, 세틸알코올 2.0㎖, 글리세릴모노스테아레이트 2.0㎖, 폴리옥시에틸렌솔비탄 모노스테아레이트 0.5㎖, 솔비탄세스퀴올레리트 0.5㎖, 글리세릴 모노스테아레이트/글리세릴 스테아레이트/폴리옥시에틸렌 스테아레이트 1.0㎖, 왁스1.0 ㎖, 유동파라핀 4.0㎖, 스쿠알란 4.0㎖, 카르릴릭/카프릭트리글리세라이드 4.0㎖, 카르복시비닐폴리머 0.3㎖, 부틸글리콜 5.0㎖, 글리세린 3.0㎖, 트리에탄올아민 0.5㎖, 향료 0.01mg, 색소 0.01mg 등을 넣고 전체가 100 g 이 되도록 정제수를 넣어 발효구아바 조성물이 함유된 화장료 조성물을 제조하였다.First, 1.5 g of the guava non-fermented composition of each of the examples or the comparative example, 2.0 g of stearic acid, 2.0 ml of cetyl alcohol, 2.0 ml of glyceryl monostearate, 0.5 ml of polyoxyethylene sorbitan monostearate, 0.5 ml of oleic acid, 1.0 ml of glyceryl monostearate / glyceryl stearate / polyoxyethylene stearate, 1.0 ml of wax, 4.0 ml of liquid paraffin, 4.0 ml of squalane, 4.0 ml of carlyric / capric triglyceride, , 5.0 ml of butyl glycol, 3.0 ml of glycerin, 0.5 ml of triethanolamine, 0.01 mg of fragrance, 0.01 mg of coloring matter and the like were added and purified water was added to make 100 g as a whole to prepare a cosmetic composition containing the fermented guava composition.
상기 화장료 조성물을, 2년 이상 아토피성 피부염을 앓고 있는 5~30 세의 아토피 환자들에게 매일 저녁 세정 후 피부에 1회 30일간 도포하게 하여 아토피성 피부염 상태 치료 정도를 측정하도록 하였다. 15명을 1군의 실험군으로 하여 4점 척도법(4: 매우 좋아졌다, 3: 보통 좋아졌다, 2: 조금 좋아졌다, 1: 변화가 없었다, 0: 더 나빠졌다)에 따라 점수를 매기도록 하고 그 평균값을 하기 <표 6>에 나타내었다. The cosmetic composition was applied to skin at least once every evening for at least 5 to 30 years old atopic patients suffering from atopic dermatitis for two years or more and then applied once to the skin for 30 days to measure the degree of treatment for atopic dermatitis. Fifteen subjects were assigned to the first group and the scores were scored according to the 4-point scale (4: much better, 3: better, 2: slightly better, 1: no change, 0: worse) The average value is shown in Table 6 below.
아토피 피부염의 치료 시작 후 30일 후에 아토피 피부염 증상의 전반적 개선도를 4단계로 구분하여 환자나 환자의 부모에게 설문지 형식으로 평가하도록 하였다. The overall improvement of atopic dermatitis symptoms was assessed in four questionnaires to patients and their parents after 30 days of treatment.
상기 <표 7>은 비교예의 구아바 비발효 조성물이 포함된 화장료 조성물은 아토피 피부염 치료 효과가 낮았으나, 구아바 발효 조성물이 포함된 화장료 조성물은 아토피 피부염 치료 효과가 높았다. 특히 실시예 4 및 8의 구아바 발효 조성물의 경우가 가장 높았다.Table 7 shows that the cosmetic composition containing the non-fermented guava composition of Comparative Example had a low therapeutic effect on atopic dermatitis, but the cosmetic composition containing the guava fermented composition was highly effective in treating atopic dermatitis. In particular, the Guava fermentation compositions of Examples 4 and 8 were the highest.
전술한 바와 같이, 본 발명에 따르면 생리 활성이 강화된 구아바 발효 조성물을 포함하는 아토피 개선제 조성물이 제공된다.As described above, according to the present invention, there is provided an atopic relief composition comprising a guava fermented composition enhanced in physiological activity.
Claims (20)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050112774 | 2005-11-24 | ||
| KR20050112774 | 2005-11-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070055373A true KR20070055373A (en) | 2007-05-30 |
| KR100847104B1 KR100847104B1 (en) | 2008-07-18 |
Family
ID=38276885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020060116297A KR100847103B1 (en) | 2005-11-24 | 2006-11-23 | Fermented guava composition and use thereof |
| KR1020060116301A KR100847104B1 (en) | 2005-11-24 | 2006-11-23 | Composition for Improving an Atopy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020060116297A KR100847103B1 (en) | 2005-11-24 | 2006-11-23 | Fermented guava composition and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (2) | KR100847103B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101147541B1 (en) * | 2010-06-09 | 2012-05-21 | 한불화장품주식회사 | A skin-care agent containing Arctii fructus extracts using microbial fermentation |
| KR20140081137A (en) * | 2012-12-21 | 2014-07-01 | 주식회사 코씨드바이오팜 | A skin-care agent containig Morchella esculenta fruit body extract or Morchella esculenta mycelium extract |
| KR101503352B1 (en) * | 2010-11-05 | 2015-03-18 | 한국생명공학연구원 | A composition for skin protection including skin aging, anti-inflammatory comprising the extracts of Lactarius hatsudake as an active ingredients |
| KR101648187B1 (en) * | 2016-02-18 | 2016-08-16 | 주식회사 비앤에이치코스메틱 | Cosmetic composition with the Omijosaeyak manufactured for improved atopy skin and skin barrier, skin moisturizing effect by Omiyaksung theory and Morchela esculenta (L.) pers fermented solution |
| US12121607B2 (en) | 2019-07-29 | 2024-10-22 | Zhejiang Yangshengtang Institute Of Natural Medication Co., Ltd. | Fermented birch sap and method for producing it |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100841453B1 (en) * | 2006-12-13 | 2008-06-26 | 농업회사법인 에스 씨 바이오텍 주식회사 | The manufacturing method of composition containing useful component from Mistletoe, and the composition |
| KR100910040B1 (en) * | 2007-07-02 | 2009-07-30 | 주식회사 엘지생활건강 | Cosmetic composition having antioxidation activity |
| KR100889605B1 (en) * | 2007-07-02 | 2009-03-20 | 주식회사 엘지생활건강 | Anti-wrinkle cosmetic composition |
| KR101423573B1 (en) * | 2007-07-02 | 2014-07-30 | 주식회사 엘지생활건강 | Cosmetic composition having antioxidation activity |
| KR100889606B1 (en) * | 2007-07-02 | 2009-03-20 | 주식회사 엘지생활건강 | Cosmetic composition for preventing of kin trouble |
| KR100889604B1 (en) * | 2007-07-02 | 2009-03-20 | 주식회사 엘지생활건강 | Whitening cosmetic composition |
| KR101012346B1 (en) * | 2008-09-18 | 2011-02-09 | (주)우성바이오 | Extract of Sparassis crispa and Its Use as Anti-inflammatory Medicine |
| KR101138411B1 (en) * | 2009-01-29 | 2012-04-26 | 김경자 | Manufacturing method of shampoo composition using fermented liquid and shampoo composition thereof |
| KR101043509B1 (en) | 2011-01-25 | 2011-06-23 | 이상권 | Preparation method of anhydride lactobaccilus fermentation health function food with respiratory organ disease and atopic dermatitis therapy improvement effects |
| JP6009080B2 (en) * | 2012-08-16 | 2016-10-19 | ユニバーシティ−インダストリー コオペレーション グループ オブ キョン ヒ ユニバーシティＵｎｉｖｅｒｓｉｔｙ−Ｉｎｄｕｓｔｒｙ Ｃｏｏｐｅｒａｔｉｏｎ Ｇｒｏｕｐ Ｏｆ Ｋｙｕｎｇ Ｈｅｅ Ｕｎｉｖｅｒｓｉｔｙ | Lactic acid bacteria having preventive and / or therapeutic activity for aging and dementia |
| KR101816647B1 (en) * | 2015-09-23 | 2018-01-09 | 코웨이 주식회사 | Cosmetic composition comprising extracts of fermented usnea longissima using hypha of cauliflower mushroom as active ingredient |
| KR101929500B1 (en) | 2018-07-27 | 2019-03-14 | 재단법인 전남생물산업진흥원 | Nano emulsion composition of guava and producing method thereof |
| KR102022400B1 (en) * | 2019-04-30 | 2019-09-18 | (주)진셀팜 | A cosmetic compositon for anti-pollution containing natural complex extract |
| KR102129585B1 (en) | 2019-05-15 | 2020-07-02 | 오가닉브릿지 주식회사 | Composition for improving atopy dermatitis, Atopic dermatitis remedy and Manufacturing method thereof |
| KR102048723B1 (en) * | 2019-07-12 | 2019-11-27 | 이혜영 | Method for manufacturing functional juice |
| KR102190166B1 (en) | 2020-02-06 | 2020-12-11 | 오가닉브릿지 주식회사 | Composition for improving atopy dermatitis, Atopic dermatitis remedy and Manufacturing method thereof |
| KR102292975B1 (en) | 2020-02-17 | 2021-08-26 | 오가닉브릿지 주식회사 | Cosmetic materials composition for skin anti-wrinkling and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof |
| KR102193712B1 (en) | 2020-02-17 | 2020-12-21 | (주)에이치투엠씨 | Cosmetic materials composition for skin-moisturizing and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof |
| KR102326796B1 (en) | 2020-02-17 | 2021-11-18 | 오가닉브릿지 주식회사 | Cosmetic materials composition for skin anti-oxidant and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof |
| KR102142426B1 (en) | 2020-02-25 | 2020-08-11 | 오가닉브릿지 주식회사 | Cosmetic materials composition for skin-whitening and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof |
| KR102160980B1 (en) | 2020-02-25 | 2020-09-29 | 오가닉브릿지 주식회사 | Cosmetic materials composition for controlling sebum and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof |
| KR102160978B1 (en) | 2020-02-25 | 2020-09-29 | 오가닉브릿지 주식회사 | Cosmetic materials composition for skin trouble care and skin-soothing, Cosmetic materials using the same and Manufacturing method thereof |
| KR102637448B1 (en) | 2021-11-16 | 2024-02-15 | 박숙우 | Cosmetic materials for improving atopy dermatitis, Manufacturing method thereof and Cosmetics containing the same |
| CN115998664B (en) * | 2023-02-01 | 2023-07-21 | 广州杨森药业有限公司 | Composition containing guava fermentation product and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4031637B2 (en) * | 2001-03-07 | 2008-01-09 | 株式会社琉球バイオリソース開発 | Fermented food, manufacturing method thereof, food and drink, and extract |
-
2006
- 2006-11-23 KR KR1020060116297A patent/KR100847103B1/en not_active IP Right Cessation
- 2006-11-23 KR KR1020060116301A patent/KR100847104B1/en not_active IP Right Cessation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101147541B1 (en) * | 2010-06-09 | 2012-05-21 | 한불화장품주식회사 | A skin-care agent containing Arctii fructus extracts using microbial fermentation |
| KR101503352B1 (en) * | 2010-11-05 | 2015-03-18 | 한국생명공학연구원 | A composition for skin protection including skin aging, anti-inflammatory comprising the extracts of Lactarius hatsudake as an active ingredients |
| KR20140081137A (en) * | 2012-12-21 | 2014-07-01 | 주식회사 코씨드바이오팜 | A skin-care agent containig Morchella esculenta fruit body extract or Morchella esculenta mycelium extract |
| KR101648187B1 (en) * | 2016-02-18 | 2016-08-16 | 주식회사 비앤에이치코스메틱 | Cosmetic composition with the Omijosaeyak manufactured for improved atopy skin and skin barrier, skin moisturizing effect by Omiyaksung theory and Morchela esculenta (L.) pers fermented solution |
| US12121607B2 (en) | 2019-07-29 | 2024-10-22 | Zhejiang Yangshengtang Institute Of Natural Medication Co., Ltd. | Fermented birch sap and method for producing it |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100847104B1 (en) | 2008-07-18 |
| KR100847103B1 (en) | 2008-07-18 |
| KR20070055372A (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100847104B1 (en) | Composition for Improving an Atopy | |
| EP2313082B1 (en) | Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment | |
| KR102144318B1 (en) | Composition for enhancing immunity comprising Ginseng berry polysaccharide | |
| CN114262667A (en) | Novel aureobasidium pullulans strain and application thereof | |
| WO2019143055A1 (en) | Composition, comprising extract of fermented beans obtained from fermentation by aspergillus fumigatus strain, for skin care improvement | |
| KR101963572B1 (en) | Composition for improving skin beauty comprising extract of fermented swallow's nest fermented with Aspergillus cristatus strain | |
| KR102111752B1 (en) | Composition for promoting collagen synthesis | |
| KR101532001B1 (en) | Cosmetics comprising fermented materials for preventing or improving skin wrinkle | |
| KR101367961B1 (en) | Compositoin for Improving Atopic Dermatitis | |
| KR20100013357A (en) | Cosmetic composition for anti-aging of the skin comprising phaseolus radiatus seed extracts by fermentation and enzyme treatment | |
| KR20180114783A (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
| CN113631227A (en) | Antiaging agent, antioxidant, antiinflammatory agent, whitening agent, and cosmetic | |
| KR102484422B1 (en) | Cosmetic composition comprising extract of Cactus and fermented product of Lactobacillus | |
| KR20170031578A (en) | Preparation method of osmotic enzyme fermentation product using dendranthema zawadskii, the fermentation product prepared thereby and cosmetic, food or pharmaceutical composition comprising the same | |
| KR102154140B1 (en) | Composition comprising tulip leaf extract, amorphophallus paeoniifolius hydrolysis extract and parrot ferment extract | |
| KR20180114782A (en) | Composition for improving skin beauty comprising extract of fermented Lentinula edodes fermented with Aspergillus cristatus strain | |
| KR102098695B1 (en) | Cosmetic Composition Containing Extracts of Morus Alba Root and Paeonia Suffruticosa Root | |
| KR101994618B1 (en) | A composition for skin smoothing comprising an extract of fermented ponciri fructus | |
| KR20160087507A (en) | cosmetic composition containing Phaseolus Radiatus Seed, Phaseolus Vulgaris (Kidney Bean) Seed and Black Soybean extracts by fermentation and enzyme treatment | |
| KR20110116389A (en) | A skin-care agent containing fermented aloe and gastrodia elata | |
| KR102710086B1 (en) | Cosmetic composition comprising fermented green tea | |
| KR102532713B1 (en) | Novel Saccharomyces cerevisiae strain and use thereof | |
| KR20110055351A (en) | Method for preparing herb fermented materials and cocmetic composition comprising the herb fermented materials | |
| KR20090081721A (en) | Cosmetic Composition for Protecting Skin Wrinkle Comprising the Fermented Extract of Phaselous radiatus | |
| KR102004149B1 (en) | Composition for improving skin beauty comprising extract of fermented rice fermented with Aspergillus cristatus strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130805 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20140703 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20150624 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20160811 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20170711 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |